Please assess the completion status of the following clinical trial:

Trial Title: Care China-Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients between the ages of 18 and 80 (inclusive) receiving CYPHER SELECT™+ Sirolimus-eluting Coronary Stent according to standard clinical practice when financially feasible~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.~* Patient has diagnosis of diabetes or is diagnosed with it before or during the index procedure hospitalization based on disease diagnosis criteria~Exclusion Criteria:~* Any contraindication to any of the following medications: aspirin, heparin, thienopyridines (clopidogrel/ticlopidine), stainless steel, contrast agents, or sirolimus~* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment~* Cardiogenic shock~* Terminal illness with life expectancy \<1 year~* ST-segment elevation myocardial infarction within 7 days prior to the index procedure~* Any patient who received coronary stent(s) within 1 year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Diabetes patients with PCI (Type: None): this is single group

Based on this trial design, predict the completion outcome and termination type (if applicable).